Drug Profile
Bivalirudin - Eagle Pharmaceuticals
Alternative Names: Bivalirudin RTU; EP-6101; Kangio; Ready-to-use bivalirudin; RTU bivalirudinLatest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Eagle Pharmaceuticals
- Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heparin-induced thrombocytopenia and thrombosis syndrome; Unstable angina pectoris
Most Recent Events
- 30 Jun 2017 Discontinued - Preregistration for Heparin-induced thrombocytopenia and thrombosis syndrome in USA (IV)
- 30 Jun 2017 Discontinued - Preregistration for Unstable angina pectoris in USA (IV)
- 15 Mar 2017 Eagle pharmaceuticals and The Medicines company has patent protection for bivalirudin in USA